Antibody Drug Conjugates Market Size

Antibody Drug Conjugates Market Size

Antibody Drug Conjugates Market size accounted for USD 7.7 billion in 2023 and is estimated to grow at CAGR of 14.8% to reach USD 26.6 billion by 2032. Increasing incidence of cancer globally coupled with growing demand for targeted therapies is expected to boost the market value.

To get key market trends

  Download Free Sample

The GLOBOCAN study carried out by the International Agency for Research on Cancer stated that in 2020, an expected of 19.3 million new cases of cancer and around 10.0 million deaths due to cancer were reported across the world. Also, antibody drug conjugates (ADCs) provide targeted delivery mechanism that allows specific recognition and binding to cancer cells, resulting in enhanced efficacy and reduced systemic toxicity compared to traditional chemotherapy.

Antibody drug conjugates (ADCs) are a class of targeted therapeutics designed to selectively deliver potent cytotoxic drugs to cancer cells. They are composed of three main components that include a monoclonal antibody, cytotoxic payload and a linker molecule. ADCs deliver the cytotoxic payload directly to the cancer cells while minimizing damage to healthy cells, thereby improving efficacy and reducing systemic toxicity associated with traditional chemotherapy. The specific targeting and payload delivery mechanisms of ADCs make them a promising approach in the field of cancer treatment.